重组溶葡萄球菌素对烧伤创面分离的金黄色葡萄球菌的体外抗菌活性评估  

Evaluation of in vitro bactericidal activity of recombinant lysostaphin against Staphylococcus aureus isolated from burn wounds

作　　者：陈旭[1] 王文奎[2] 孟志民[3] 王雅[3] 邵妍妍[3] 韦栋[3] 樊宁远[3] 倪语星[1] 韩立中[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院临床微生物科,上海200025 [2]上海交通大学医学院附属瑞金医院烧伤科,上海200025 [3]上海交通大学医学院附属瑞金医院临床医学院检验系,上海200025

出　　处：《上海交通大学学报（医学版）》2012年第11期1411-1414,共4页Journal of Shanghai Jiao tong University:Medical Science

基　　金：上海市自然科学基金(09ZR1419200);卫生公益性行业科研专项基金(201002021)~~

摘　　要：目的评估重组溶葡萄球菌素对烧伤创面分离的金黄色葡萄球菌的体外抗菌活性。方法收集烧伤创面分离的金黄色葡萄球菌共171株。采用琼脂稀释法测定临床烧伤常用药物万古霉素、红霉素、克林霉素、头孢西丁及磺胺甲噁唑对金黄色葡萄球菌的最低抑菌浓度(MIC);根据头孢西丁的MIC值区分耐甲氧西林的金黄色葡萄球菌(MRSA)和甲氧西林敏感的金黄色葡萄球菌(MSSA);根据万古霉素、红霉素、克林霉素、磺胺甲噁唑的药物敏感试验结果对金黄色葡萄球菌进行耐药性分析。采用微量肉汤稀释法检测重组溶葡萄球菌素对金黄色葡萄球菌的MIC,计算50%最低抑菌浓度(MIC50)和90%最低抑菌浓度(MIC90)。结果根据药物敏感试验结果,收集的171株金黄色葡萄球菌对磺胺甲噁唑、红霉素、克林霉素和万古霉素的耐药率分别为99.4%、88.3%、87.1%和0,其中MRSA有146株(占85.4%)。重组溶葡萄球菌素对金黄色葡萄球菌的MIC范围为0.015～0.5 U/mL,MIC50为<0.015 U/mL,MIC90为0.03 U/mL。结论重组溶葡萄球菌素对金黄色葡萄球菌具有较好的体外抗菌活性。在金黄色葡萄球菌耐药性日益增强的情况下,对于临床烧伤创面感染的预防和治疗,重组溶葡萄球菌素是一种极具开发潜力的新药。Objective To evaluate the in vitro bactericidal activity of recombinant lysostaphin against Staphylococcus aureus isolated from burn wounds. Methods One hundred and seventy-one Staphylococcus aureus strains were isolated from burn wounds. The minimum inhibitory concentrations （MIC） of vancomycin, erythromycin, clindamycin, cefoxitin and sulfamethoxazole, which were common drugs used for burns in clinics against Staphylococcus aureus were measured by agar dilution method. Methicillin-resistant Staphylococcus aureus （MRSA） and methicillin-sensitive Staphylococcus aureus （MSSA） were divided according to the MIC of cefoxitin. Drug resistance analysis of Staphylococcus aureus was conducted according to the results of antimicrobial susceptibility tests of vancomycin, erythromycin, clindamycin and sulfamethoxazole. The MIC of recombinant lysostaphin against Staphylococcus aureus was measured by micro-broth dilution method, and 50% minimun inhibitory concentration （MICs0） and 90% minimun inhibitory concentration （MICg0） were calculated. Results According to the results of antimicrobial susceptibility tests, the resistance rates of Staphylococcus aureus to sulfamethoxazole, erythromycin, clindamycin and vancomycin were 99.4%, 88.3%, 87.1% and 0 respectively, and the prevalence of MRSA was 85. 4% （ 146 strains）. The MIC of recombinant lysostaphin against Staphylococcus aureus ranged from 0. 015 to 0.5 U/mL, with MIC50 of 〈 0. 015 U/mL and MIC90 of 0.03 U/mL. Conclusion Recombinant lysostaphin has favorable in vitro bactericidal activity against Staphylococcus aureus, With the increasing resistance of Staphylococcus aureus to clinical drugs, recombinant lysostaphin may potentially be a potent drug for Staphylococcus aureus infection of the burn wounds.

关 键 词：重组溶葡萄球菌素 金黄色葡萄球菌 体外抗菌活性 最低抑菌浓度 烧伤 

分 类 号：R644[医药卫生—外科学]